As an HDAC1 inhibitor, FK228 (depsipeptide) can act on non‐histone targets to enhance the anti‐tumour effect of TKI erotinib (for the treatment of NSCLC) by inhibiting the MAPK pathway18.19 The gene discussed is HDAC1; the disease is neoplasm.